[Federal Register Volume 60, Number 70 (Wednesday, April 12, 1995)]
[Notices]
[Page 18618]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-8918]



-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE

Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec. 1301.43(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 16, 1994, Knoll 
Pharmaceuticals, 30 North Jefferson Road, Whippany, New Jersey 07981, 
made application to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the Schedule II controlled 
substance Hydromorphone (9150).
    The firm plans to produce Hydromorphone bulk product and finished 
dosage units of Dilaudid for distribution to its customers.
    Any other such application and any person who is presently 
registered with DEA to manufacture such substances may file comments to 
objections to the issuance of the above application and may also file a 
written request for a hearing thereon in accordance with 21 CFR 1301.54 
and in the form prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, United States Department of 
Justice, Washington, DC 20537, Attention: DEA Federal Register 
Representative (CCR), and must be filed no later than May 12, 1995.

    Dated: April 4, 1995.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 95-8918 Filed 4-11-95; 8:45 am]
BILLING CODE @4410-09-M